U.K. Competition Watchdog Weighs Potential Impact of Roche-LumiraDx Deal
By Mauro Orru
The U.K.'s Competition and Markets Authority is considering whether a deal for Roche Holding to buy certain companies linked to LumiraDx's point-of-care technology could stifle competition in the country.
The CMA said Monday that it is seeking comments from any interested party until June 3 to inform its views on the deal, though it hasn't yet launched a formal investigation into the transaction.
Roche and LumiraDx struck an agreement in December. The companies didn't respond to requests for comment.
Write to Mauro Orru at mauro.orru@wsj.com
(END) Dow Jones Newswires
May 20, 2024 02:38 ET (06:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations